- Home
- Our Investigators
- Sarah Taylor, MD, PhD
Sarah Taylor, MD, PhD
Assistant Professor of Gynecologic Oncology
My research focuses on design and conduct of clinical trials with a particular focus on novel therapies for gynecologic cancers. I approach this through a wholistic lens collaborating with translational scientists, epidemiologists and researchers who focus on cancer care support, like patient reported outcomes, advocacy and quality of life. This allows for novel and innovative ways to make sure that we are caring for individuals and not just treating cancer.
Sarah Taylor, MD, PhD
Research in Brief
Dr. Taylor’s research is dedicated to improving carefor individuals with gynecologic cancers by identifying new drug targets and developing clinical trials that personalize therapy. Her goal is to increase survival and improve quality of life for patients facing these challenging cancers.
Current Projects
- Development and implementation of early-phase clinical trials for gynecologic malignancies.
- Quality improvement initiatives for genetic and tumor testing to improve identification of hereditary predispositions to cancer and improve targeted therapeutic outcomes.
- Integration of therapeutic and supportive clinical trials into standard clinical practice to improve cancer care delivery
Selected Publications
- Taylor SE, Mai PL, Donovan H, Bell SG, Rush SK, Edwards RP, Buckanovich RJ, Smith KJ. Cost-Effectiveness Analysis of Tumor Testing for BRCA Pathogenic Variants in Epithelial Ovarian Cancer. Am J Clin Oncol. 2025 Mar 26. doi: 10.1097/COC.0000000000001187. Epub ahead of print. PMID: 40138181.
- Taylor SE, Behr S, Cooper KL, Mahdi H, Fabian D, Gallion H, Ueland F, Vargo J, Orr B, Girda E, Courtney-Brooks M, Olawaiye AB, Randall LM, Richardson DL, Sullivan SA, Huang M, Christner SM, Beriwal S, Lin Y, Chauhan A, Chu E, Kohn EC, Kunos C, Ivy SP, Beumer JH. Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892). Cancer Chemother Pharmacol. 2024 Dec 14;95(1):4. doi: 10.1007/s00280-024-04720-1. PMID: 39673591.
- Thomas TH, Bender C, Rosenzweig M, Taylor S, Sereika SM, Babichenko D, You KL, Terry MA, Sabik LM, Schenker Y. Testing the effects of the Strong Together self-advocacy serious game among women with advanced cancer: Protocol for the STRONG randomized clinical trial. Contemp Clin Trials. 2022 Nov 13;124:107003. doi: 10.1016/j.cct.2022.107003. Epub ahead of print. PMID: 36379436.
- Taylor, SE, Chan, DK, Yang, D, Bruno, T, Lieberman, R, Siddiqui, J, Soong, TR; Coffman, L, Buckanovich, RJ. Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer. Cancers (Basel). 2022 May 5;14(9):2298. doi: 10.3390/cancers14092298. PMID: 35565427; PMCID: PMC9104826.
- Lemon LS, Orr B, Modugno F, Buckanovich RJ, Coffman L, Edwards RP, Taylor S. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Gynecol Oncol. 2022 Feb 6:S0090-8258(22)00049-X. doi: 10.1016/j.ygyno.2022.01.022. Epub ahead of print. PMID: 35140015
For additional publications, click here.
Research Group
Ronald Buckanovich, MD, PhD
Lan Coffman, PhD
Francesmary Modugno, PhD
Heidi Donovan, RN, PhD
Teresa Thomas, RN, PhD
Phuong Mai, MD
In the News
Sep 18, 2024
Reimagining How We Treat Cancer